<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02790515</url>
  </required_header>
  <id_info>
    <org_study_id>REF2HCT</org_study_id>
    <secondary_id>NCI-2016-00812</secondary_id>
    <nct_id>NCT02790515</nct_id>
  </id_info>
  <brief_title>Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation</brief_title>
  <official_title>Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Children's Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Children's Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to examine treatment therapy that will reduced regimen-related toxicity and&#xD;
      relapse while promoting rapid immune reconstitution with limited serious&#xD;
      graft-versus-host-disease (GVHD) and also improve disease-free survival and quality of life.&#xD;
      The investigators propose to evaluate the safety and efficacy of selective naive T-cell&#xD;
      depleted (by TCRɑβ and CD45RA depletion, respectively) haploidentical hematopoietic cell&#xD;
      transplant (HCT) following reduced intensity conditioning regimen that avoids radiation in&#xD;
      patients with hematologic malignancies that have relapsed or are refractory following prior&#xD;
      allogeneic transplantation.&#xD;
&#xD;
      PRIMARY OBJECTIVE:&#xD;
&#xD;
        -  To estimate engraftment by day +30 post-transplant in patients who receive&#xD;
           TCRɑβ-depleted and CD45RA-depleted haploidentical donor progenitor cell transplantation&#xD;
           following reduced intensity conditioning regimen without radiation.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
        -  Assess the safety and feasibility of the addition of Blinatumomab in the early&#xD;
           post-engraftment period in patients with CD19+ malignancy.&#xD;
&#xD;
        -  Estimate the incidence of malignant relapse, event-free survival, and overall survival&#xD;
           at one-year post-transplantation.&#xD;
&#xD;
        -  Estimate incidence and severity of acute and chronic (GVHD).&#xD;
&#xD;
        -  Estimate the rate of transplant related mortality (TRM) in the first 100 days after&#xD;
           transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Blood progenitor cells will be obtained from a partially matched adult family member (donor).&#xD;
      After processing and filtration using the CliniMACS device, cells will be infused into&#xD;
      participants meeting eligibility criteria.&#xD;
&#xD;
      Prior to transplant, participants will receive a conditioning treatment of rabbit ATG,&#xD;
      cyclophosphamide, fludarabine, thiotepa, melphalan, and rituximab. Mesna will be given to&#xD;
      help prevent side effects of cyclophosphamide. Tacrolimus will be given to help reduce the&#xD;
      risk of GVHD. G-CSF will be given after transplant to help the donor progenitor cells make&#xD;
      white blood cells faster so that the immune system is better able to fight infection.&#xD;
&#xD;
      Blood progenitor cells will be given in two infusions on Day 0 and Day +1. Progenitor cells&#xD;
      then move through the blood stream to the bone marrow space where they should begin to grow.&#xD;
      Participant blood will be monitored for 100 days to assure that the progenitor cells begin to&#xD;
      grow. If the growth is low, additional progenitor cells may be given.&#xD;
&#xD;
      Blood tests will be monitored for up to one year to observe how well the donor cells grow and&#xD;
      their effect on the infection-fighting system.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 14, 2016</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of patients engrafted by day +30 post-transplant</measure>
    <time_frame>30 days post-transplant</time_frame>
    <description>ANC engraftment is defined as the first of 3 consecutive tests performed on different days of an ANC ≥ 500/mm^3 with evidence of donor cell engraftment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of patients experiencing Blinatumomab permanent discontinuation due to toxicity</measure>
    <time_frame>3 months post-transplant</time_frame>
    <description>If the drug is held for more than 2 weeks due to toxicity, it will be permanently discontinued.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The estimate of cumulative incidence of relapse</measure>
    <time_frame>One year post-transplant</time_frame>
    <description>The estimate of cumulative incidence of relapse will be estimated using Kalbfleisch-Prentice method. Death is the competing risk event. The Kaplan-Meier estimates of overall survival (OS) and event-free survival (EFS) along with their standard errors will be calculated.&#xD;
OS is defined as time from transplantation to death or last follow-up, whichever comes first. EFS is defined as time from transplantation to events including relapse, graft failure, death due to any cause and last follow-up whichever comes first. The participants surviving at the time of analysis without events will be censored.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The cumulative incidence of acute and chronic Graft-Versus-Host Disease (GVHD)</measure>
    <time_frame>One year post transplant</time_frame>
    <description>The cumulative incidence of acute and chronic GVHD will be estimated using Kalbfleisch-Prentice method. Death is the competing risk event. GVHD will be reported separately for participants receiving tacrolimus and those receiving sirolimus.&#xD;
The severity of acute GVHD and chronic GVHD will be described.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The cumulative incidence of transplant related mortality</measure>
    <time_frame>100 days post transplant</time_frame>
    <description>The cumulative incidence of transplant related mortality will be estimated using Kalbfleisch-Prentice method. Deaths before day 100 because of other reasons are the competing risk events.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Acute Lymphoblastic Leukemia (ALL)</condition>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <condition>Myeloid Sarcoma</condition>
  <condition>Chronic Myeloid Leukemia (CML)</condition>
  <condition>Juvenile Myelomonocytic Leukemia (JMML)</condition>
  <condition>Myelodysplastic Syndrome (MDS)</condition>
  <condition>Non-Hodgkin Lymphoma (NHL)</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a conditioning regimen of antithymocyte globulin (rabbit), cyclophosphamide, mesna, fludarabine, thiotepa, tacrolimus (first 5 participants enrolled), sirolimus (used beginning with 6th enrolled participant), melphalan, rituximab. This is followed by HPC,A infusion (transplant), then by G-CSF and blinatumomab.&#xD;
Cells for infusion are prepared using the CliniMACS System.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-thymocyte globulin (rabbit)</intervention_name>
    <description>Given intravenous (IV) prior to transplant on Days -14, -13, -12.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Thymoglobulin®</other_name>
    <other_name>rabbit ATG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Blinatumomab</intervention_name>
    <description>Given by continuous IV infusion at least 2 weeks post-engraftment. Blinatumomab will be given only to patients with CD19+ malignancies.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Blincyto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given by IV infusion prior to transplant on Day -9.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given IV prior to transplant on Days -8, -7, -6, -5, and -4.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>Given IV or subcutaneous (SQ) following transplant on Days 6 and 7.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Filgrastim</other_name>
    <other_name>Neupogen®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Given IV prior to transplant on Days -2 and -1.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>L-phenylalanine mustard</other_name>
    <other_name>Phenylalanine mustard</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-sarcolysin</other_name>
    <other_name>Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesna</intervention_name>
    <description>Given IV prior to cyclophosphamide administration and at approximately 3, 6, and 9 hours after cyclophosphamide infusion.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Mesnex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Given IV prior to transplant on Day -1.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Rituxan™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given oral (PO) or IV beginning prior to transplant on Day -2. The dose will begin to taper at approximately day +60 after transplant in the absence of GVHD. Tacrolimus was used for the first 5 participants enrolled on study. Subsequent participants receive sirolimus.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>FK506</other_name>
    <other_name>Prograf®</other_name>
    <other_name>Protopic®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>Given IV prior to transplant on Day -3.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Thioplex® by Immunex</other_name>
    <other_name>TESPA</other_name>
    <other_name>TSPA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HPC,A Infusion</intervention_name>
    <description>Hematopoietic Progenitor Cell, Apheresis (HPC,A) infusion of TCRɑβ+ depleted cells on day of transplant (Day 0) and HPC,A infusion of CD45RA+ depleted cells on Day +1 following transplant.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Transplant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CliniMACS</intervention_name>
    <description>The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Cell Selection System</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Given orally (PO) starting Day 0. The dose will be tapered off over two weeks starting on Day +42 in the absence of GVHD.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Rapamycin</other_name>
    <other_name>Rapamune®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Transplant Recipient:&#xD;
&#xD;
          -  Age less than or equal to 21 years.&#xD;
&#xD;
          -  Any of the following hematologic malignancies that has relapsed or remains refractory&#xD;
             after prior allogeneic HCT (this includes any stage of disease - such as refractory&#xD;
             due to induction failure, refractory in relapse, or in any CR - as long as the&#xD;
             hematologic malignancy remained persistent or returned after a previous allogeneic&#xD;
             HCT):&#xD;
&#xD;
               -  ALL, AML, Myeloid Sarcoma, CML, Juvenile myelomonocytic leukemia (JMML),&#xD;
                  myelodysplastic syndrome (MDS), non-Hodgkin lymphoma (NHL)&#xD;
&#xD;
          -  Has a suitable single haplotype matched (≥ 3 of 6) family member donor.&#xD;
&#xD;
          -  Does not have any other active malignancy other than the one for which this transplant&#xD;
             is indicated.&#xD;
&#xD;
          -  If prior CNS leukemia, it must be treated and in CNS CR&#xD;
&#xD;
          -  Does not have current uncontrolled bacterial, fungal, or viral infection.&#xD;
&#xD;
          -  There is no minimum time from the previous transplant, but patients must meet the&#xD;
             following criteria:&#xD;
&#xD;
               -  Left ventricular ejection fraction &gt; 40%, or shortening fraction ≥ 25%.&#xD;
&#xD;
               -  Creatinine clearance (CrCl) or glomerular filtration rate (GFR) ≥ 50&#xD;
                  ml/min/1.73m2.&#xD;
&#xD;
               -  Forced vital capacity (FVC) ≥ 40% of predicted value; or pulse oximetry ≥ 92% on&#xD;
                  room air if patient is unable to perform pulmonary function testing.&#xD;
&#xD;
               -  Karnofsky or Lansky (age-dependent) performance score ≥ 50 (See Appendix A).&#xD;
&#xD;
               -  Bilirubin ≤ 3 times the upper limit of normal for age.&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 5 times the&#xD;
                  upper limit of normal for age.&#xD;
&#xD;
               -  Not pregnant. If female with child bearing potential, must be confirmed by&#xD;
                  negative serum or urine pregnancy test within 14 days prior to enrollment.&#xD;
&#xD;
               -  Not breast feeding&#xD;
&#xD;
        Inclusion Criteria for Haploidentical Donor:&#xD;
&#xD;
          -  At least single haplotype matched (≥ 3 of 6) family member&#xD;
&#xD;
          -  At least 18 years of age.&#xD;
&#xD;
          -  HIV negative.&#xD;
&#xD;
          -  Not pregnant as confirmed by negative serum or urine pregnancy test within 14 days&#xD;
             prior to enrollment (if female).&#xD;
&#xD;
          -  Not breast feeding.&#xD;
&#xD;
          -  Regarding donation eligibility, is identified as either:&#xD;
&#xD;
               -  Completed the process of donor eligibility determination as outlined in 21 CFR&#xD;
                  1271 and agency guidance; OR&#xD;
&#xD;
               -  Does not meet 21 CFR 1271 eligibility requirements, but has a declaration of&#xD;
                  urgent medical need completed by the principal investigator or physician&#xD;
                  sub-investigator per 21 CFR 1271.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brandon Triplett, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Jude Children's Research Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brandon Triplett, MD</last_name>
    <phone>866-278-5835</phone>
    <email>referralinfo@stjude.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandon Triplett, MD</last_name>
      <phone>866-278-5833</phone>
      <email>referralinfo@stjude.org</email>
    </contact>
    <investigator>
      <last_name>Brandon Triplett, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stjude.org</url>
    <description>St. Jude Children's Research Hospital</description>
  </link>
  <link>
    <url>http://www.stjude.org/protocols</url>
    <description>Clinical Trials Open at St. Jude</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 31, 2016</study_first_submitted>
  <study_first_submitted_qc>May 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2016</study_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Sarcoma, Myeloid</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Mechlorethamine</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Blinatumomab</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

